Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics Inc (TARA) is a clinical-stage biotechnology company developing transformative therapies for cancer and rare diseases. This page provides investors and industry observers with timely updates on clinical trials, regulatory milestones, and corporate developments.
Access comprehensive coverage of TARA's investigational cell therapy TARA-002 for lymphatic malformations and IV Choline Chloride research. Our news collection features press releases, peer-reviewed data publications, and strategic partnership announcements.
Key updates include progress reports on:
• Clinical trial phases
• FDA designations
• Scientific conference presentations
• Intellectual property developments
Bookmark this page for centralized access to Protara's latest advancements in immunopotentiator therapies and metabolic replacement solutions. Monitor critical updates affecting the company's position in the oncology and rare disease treatment landscapes.
Protara Therapeutics (TARA) reported third-quarter 2020 results, highlighting a strong cash position of $166M as of September 30, and a net loss of $8M, compared to $2.4M in Q3 2019. The company confirmed initial comparability between TARA-002 and OK-432, with plans to complete GMP batch runs by mid-2021. Protara is set to initiate a Phase 1 trial for TARA-002 in non-muscle invasive bladder cancer in 2021 and has requested an FDA meeting to discuss the regulatory path for TARA-002 in lymphatic malformations. R&D expenses surged to $2.8M, with general and administrative costs reaching $5.3M.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced that CEO Jesse Shefferman will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 1:45 PM ET. A webcast of the presentation will be available on the Company’s website and archived for 90 days. Protara focuses on developing transformative therapies for cancer and rare diseases, including TARA-002 for non-muscle invasive bladder cancer and IV Choline Chloride for intestinal failure-associated liver disease. For more details, visit www.protaratx.com.
Protara Therapeutics (Nasdaq: TARA) has issued inducement non-qualified stock options for 5,200 shares to two new employees. The exercise price is set at $17.84, the closing price on November 2, 2020. Vesting occurs over four years, with 25% vesting after one year and the remainder monthly over 36 months, contingent upon continued employment. This grant complies with NASDAQ Listing Rule 5635(c)(4). Protara focuses on innovative therapies for cancer and rare diseases, including TARA-002 for bladder cancer and IV Choline Chloride for liver disease.
Protara Therapeutics (Nasdaq: TARA) announced the pricing of two underwritten public offerings, totaling 4,600,000 shares of common stock at $16.87 each and 4,148 shares of non-voting Series 1 Convertible Preferred Stock priced at $16,873.54 each, expected to close on September 24, 2020. The company anticipates receiving $147.6 million in gross proceeds, primarily for development activities associated with its lead therapy, TARA-002, targeting non-muscle invasive bladder cancer and lymphatic malformations. The offerings are conducted under an effective shelf registration statement.
Protara Therapeutics (Nasdaq: TARA) announced advancements in the clinical development of its lead therapy, TARA-002, for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations. Following constructive discussions with the FDA, initial comparability between TARA-002 and OK-432 has been confirmed, with further GMP runs planned for mid-2021. A Phase 1 study for NMIBC is set for 2021, with Phase 2 anticipated in 2022. The company will also seek a meeting with the FDA regarding TARA-002’s BLA for lymphatic malformations, supported by positive historical data from OK-432.
Protara Therapeutics (Nasdaq: TARA) announced the granting of 27,500 inducement stock options to two new employees, priced at $20.51 per share, the closing price on September 1, 2020. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter. This approval aligns with NASDAQ Listing Rule 5635(c)(4). Protara focuses on developing treatments for rare diseases, including its lead program TARA-002 for lymphatic malformations and IV Choline Chloride for IFALD.
Protara Therapeutics (Nasdaq: TARA) announced FDA's Rare Pediatric Disease designation for TARA-002, aimed at treating Lymphatic Malformations (LMs), which are rare congenital conditions. TARA-002 is a cell-based therapy utilizing the immunopotentiator OK-432, already approved in Japan and Taiwan. A Phase 2 trial showed promising results, with 86% of pediatric patients displaying significant response. This designation highlights the urgent medical need for LMs treatment, and Protara is poised to explore further development steps with the FDA.
Protara Therapeutics (TARA) announced the appointment of Barry P. Flannelly, Pharm.D, to its Board of Directors, replacing Scott Braunstein, M.D. Dr. Flannelly brings over 20 years of experience in the pharmaceutical and biotech sectors, currently serving as Executive Vice President at Incyte. CEO Jesse Shefferman expressed optimism about leveraging Dr. Flannelly's expertise to advance Protara's lead program, TARA-002, aimed at treating lymphatic malformations. The transition occurs at a pivotal time for Protara as it seeks to enhance its drug development pipeline.
Protara Therapeutics (Nasdaq: TARA) announced the grant of inducement stock options for 3,700 shares to a new employee, with an exercise price of $28.20, matching the closing price on July 1, 2020. The options will vest over four years, with 25% vesting after one year and the remainder monthly thereafter, contingent on continued employment. This move aligns with NASDAQ Listing Rule 5635(c)(4) and indicates Protara's commitment to attracting talent essential for advancing its clinical programs aimed at treating rare diseases.
